Pharma News

Pharma Courses 
PAGE Admission

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
    2 October 2021

    Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

    Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficiency of IDS and manifests in different forms.

  • 2 October 2021
    Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

    Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

    The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

  • 2 October 2021
    NPPA condemns false statements regarding its connivance in any malpractices adopted by Pharmaceutical Companies

    National Pharmaceutical Pricing Authority is a regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India and is committed to ensure affordability and accessibility of medicines by fixing the ceiling price for scheduled formulations and monitoring the prices of non-scheduled formulations.

  • 1 October 2021
    Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.

  • 1 October 2021
    BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

    MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE announced that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients.

  • 1 October 2021
    Gujarat State Pharmacy Council to offer financial assistance to family of pharmacist who died in Corona pandemic

    ​Gujarat State Pharmacy Council (GSPC) had organised celebration of World Pharmacist Day on 25th Sept 2021 in which more than 300 pharmacists from the pharmacy sector of the state of Gujarat were present. In this event GSPC announced financial assistance to the family of a Gujarat pharmacist who died while on duty in Corona pandemic.

  • 28 September 2021
    DBT Institute to help Vietnamese company develop COVID vaccine

     After helping several Indian companies in the development of vaccines for COVID-19 including clinical trials, the Department of Biotechnology (DBT)’s Translational Health Science and Technology Institute (THSTI) has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company which is in the process of developing a vaccine for the disease.

  • 28 September 2021
    Gut bacteria influence brain development

    Extremely premature infants are at a high risk for brain damage. Researchers at the University of Vienna and the Medical University of Vienna have now found possible targets for the early treatment of such damage outside the brain: Bacteria in the gut of premature infants may play a key role. The research team found that the overgrowth of the gastrointestinal tract with the bacterium Klebsiella is associated with an increased presence of certain immune cells and the development of neurological damage in premature babies.

  • 28 September 2021
    COVID-19 has caused the biggest decrease in life expectancy since World War II

    The research team assembled an unprecedented dataset on mortality from 29 countries, spanning most of Europe, the US and Chile – countries for which official death registrations for 2020 had been published. They found that 27 of the 29 countries saw reductions in life expectancy in 2020, and at a scale which wiped out years of progress on mortality, according to the paper published today in the International Journal of Epidemiology.

  • 27 September 2021
    AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg Capsule

    AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule.

    Selumetinib can also cause cardiomyopathy, ocular toxicity including retinal vein occlusion, retinal pigment epithelial detachment and impaired vision, and increased creatinine phosphokinase. Selumetinib should be withheld, dosage reduced, or permanently discontinued based on the severity of adverse reactions.

Subscribe to Pharma News